AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy
Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.
Pharma & Biotech